Taken together, our case demonstrates that DPP-4 inhibitors, while most often associated with BP, can rarely precipitate EBA, and that this may be accompanied by additional systemic autoimmune manifestations such as ITP. This evidence concerns the gene DPP4 and autoimmune thrombocytopenic purpura.